United Therapeutics (NASDAQ:UTHR) Director Jan Malcolm Sells 325 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 325 shares of the company’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $550.59, for a total transaction of $178,941.75. Following the sale, the director directly owned 450 shares of the company’s stock, valued at $247,765.50. The trade was a 41.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Price Performance

Shares of UTHR traded down $5.42 on Friday, reaching $547.06. The company’s stock had a trading volume of 301,306 shares, compared to its average volume of 526,796. The stock has a market capitalization of $23.22 billion, a P/E ratio of 20.19, a PEG ratio of 1.81 and a beta of 0.58. The stock’s 50 day simple moving average is $556.70 and its two-hundred day simple moving average is $529.44. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the firm posted $6.63 earnings per share. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. Analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. HC Wainwright boosted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $644.82.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. bought a new position in United Therapeutics in the 3rd quarter worth $317,617,000. Norges Bank purchased a new stake in United Therapeutics in the 4th quarter worth $293,418,000. Avoro Capital Advisors LLC increased its stake in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after acquiring an additional 341,383 shares during the period. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.